Skip to content

Role of indomethacin suppository as a possible means to reduce complications related to Pancreatoduodenectomy.

Efficacy of Rectal Indomethacin in prevention of post-operative pancreatitis after pancreaticoduodenectomy â?? a randomized controlled trial

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/028027
Enrollment
80
Registered
2020-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K860- Alcohol-induced chronic pancreatitis Health Condition 2: K862- Cyst of pancreas Health Condition 3: C241- Malignant neoplasm of ampulla of Vater Health Condition 4: C240- Malignant neoplasm of extrahepaticbile duct Health Condition 5: C250- Malignant neoplasm of head of pancreas Health Condition 6: K831- Obstruction of bile duct Health Condition 7: K861- Other chronic pancreatitis Health Condition 8: K838- Other specified diseases of biliary tract

Interventions

Intervention1: 100mg of Indomethacin Suppository: Single Dose 100mg Indomethacin Suppository administered Per-rectally at the time of Induction of Anesthesia prior to Pancreatoduodenectomy. Control In

Sponsors

Institute of Liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All consenting adults planned to undergo pancreatoduodenectomy

Exclusion criteria

Exclusion criteria: 1. Patients refusing to consent 2. History of asthma 3. History of allergic reactions to NSAIDs 4. History of renal dysfunction or CKD 5. E/o Internal hemorrhoids on examination 6. Patients on Anti-platelet drugs

Design outcomes

Primary

MeasureTime frame
Incidence of Post-operative PancreatitisTimepoint: Within 30 days of surgery

Secondary

MeasureTime frame
Delayed Gastric emptying rateTimepoint: within 30 days of surgery;Duration of ICU stayTimepoint: within 30 days of surgery;Intra-abdominal collections/abscess ratesTimepoint: within 30 days of surgery;Length of Hospital StayTimepoint: within 30 days of surgery;Post-operative pancreatic fistula rateTimepoint: within 30 days of surgery;Post-pancreaticoduodenectomy hemorrhage rateTimepoint: within 30 days of surgery;Risk factors for post-operative pancreatitisTimepoint: within 30 days of surgery

Countries

India

Contacts

Public ContactDr Anubhav

Institute of Liver and Biliary Sciences

viniyendra@yahoo.co.uk9540946803

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026